Cartesian Therapeutics
RNAC
57 hedge funds and large institutions have $144M invested in Cartesian Therapeutics in 2018 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 31 increasing their positions, 8 reducing their positions, and 11 closing their positions.
529% more call options, than puts
Call options by funds: $44K | Put options by funds: $7K
288% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 8
38% more capital invested
Capital invested by funds: $105M → $144M (+$39.8M)
0.09% more ownership
Funds ownership: 1.53% → 1.62% (+0.09%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 59 → 57 (-2)
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$5.4M |
| 2 |
AG
Artal Group
Luxembourg
|
+$4.43M |
| 3 |
BlackRock
New York
|
+$3.01M |
| 4 |
Millennium Management
New York
|
+$1.41M |
| 5 |
Man Group
London,
United Kingdom
|
+$1.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$6.05M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.65M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$495K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$490K |
RNAC Hedge Fund Activity: Q2 2018 in Review
57 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q2 2018, worth a combined $144M — up 38% from $105M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of RNAC and 9 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 31 added.
The largest buyer was Kennedy Capital Management, adding an estimated $5.4M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $6.05M sold.
- 57 institutional investors held Cartesian Therapeutics (RNAC) as of Q2 2018, down from 59 in Q1 2018.
- Funds reported $144M of Cartesian Therapeutics stock for Q2 2018, up 38% quarter-over-quarter.
- 9 funds opened new Cartesian Therapeutics positions in Q2 2018 and 11 closed out, a net change of -2 holders.
- The largest Cartesian Therapeutics buyer in Q2 2018 was Kennedy Capital Management, an estimated $5.4M added.
- The largest Cartesian Therapeutics seller in Q2 2018 was Perceptive Advisors, an estimated $6.05M sold.
Based on aggregated 13F filings for Q2 2018.